Opinion|Videos|February 21, 2025
Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL
Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), particularly in optimizing treatment duration and sequencing to improve patient outcomes.
Advertisement
Episodes in this series
- Were there any particularly exciting updates or data presented at ASH 2024 that could influence how BTK inhibitors are used in clinical practice for CLL and MCL?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale
2
ACA Enrollment Erosion Deepens After Open Enrollment Ends
3
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
4
Efgartigimod Effective in Broad Subsets of Patients With gMG
5